在III期ICON9研究（NCT03278717）中，与单独使用奥拉帕利（Olaparib）相比，奥拉帕利联合Cediranib（西地尼布）用于复发性铂敏感卵巢癌的维持治疗并未 ...

The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib. Men in the study ...

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...

The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Around 500 men with advanced prostate cancer and 300 women with HER2-negative early ...

The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Some 800 people in total will be eligible for the treatment. Around 500 men with advanced ...

Up to 600 women with a hereditary type of the disease could benefit each year. Health bosses said olaparib had the potential to make "a huge impact", giving a better chance of survival.

AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the CDSCO, ...

Olaparib monotherapy may be a treatment option for some patients with high-risk biochemically recurrent prostate cancer, according to researchers.

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...